Skip to main content
Karger Publishers - PMC COVID-19 Collection logoLink to Karger Publishers - PMC COVID-19 Collection
. 2021 Mar 18:1–5. doi: 10.1159/000515340

SARS-CoV-2 Lineages and Sub-Lineages Circulating Worldwide: A Dynamic Overview

Eleonora Cella a,**, Francesca Benedetti b, Silvia Fabris c, Alessandra Borsetti d, Aldo Pezzuto e, Marco Ciotti f, Stefano Pascarella g, Giancarlo Ceccarelli h, Davide Zella b, Massimo Ciccozzi c, Marta Giovanetti i,j,*
PMCID: PMC8089399  PMID: 33735881

Abstract

Background

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) originated in Wuhan, China, in early December 2019 has rapidly widespread worldwide, becoming one of the major global public health issues of the last centuries.

Key Messages

Over the course of the pandemic, due to the advanced whole-genome sequencing technologies, an unprecedented amount of genomes have been generated, providing invaluable insights into the ongoing evolution and epidemiology of the virus during the pandemic. Therefore, this large amount of data played an important role in the SARS-CoV-2 mitigation and control strategies.

Key Messages

The active monitoring and characterization of the SARS-CoV-2 lineages circulating worldwide is useful for a more specific diagnosis, better care, and timely treatment. In this review, a concise characterization of all the lineages and sub-lineages circulating and co-circulating across the world has been presented in order to determine the magnitude of the SARS-CoV-2 threat and to better understand the virus genetic diversity and its dispersion dynamics.

Keywords: SARS-CoV-2, Lineages, Pandemic, Genome diversity, Prevention strategies

Introduction

On December 31, 2019, the WHO country office in China acknowledged unusual viral pneumonia cases in Wuhan. The responsible agent has been identified as a new coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1 ] and the associated symptoms are referred to as coronavirus disease 2019 (COVID-19) [2 ]. This virus belongs to the Betacoronavirus genus, and its genome is composed of 29,903 nucleotides [3 ]. Its genome organization is shared with other Betacoronaviruses, and it presents 6 functional open reading frames (ORFs) that are arranged in order from 5′ to 3′: replicase (ORF1a/ORF1b), spike (S), envelope, membrane, and nucleocapsid [4 ].

The epidemic peak in China was reached in early February 2020, and the Chinese government implemented strict measures to contain SARS-CoV-2 spread, including gathering restrictions and travel ban [5 ]. Whereas in China, new cases decreased, worldwide SARS-CoV-2 infections started to increase. Following the viral spread worldwide, the WHO declared the outbreak as a Public Health Emergency of International Concern on January 30, 2020, and a pandemic on March 11, 2020. Since the first detection in China in December 2019, more that 77 million cases have been registered worldwide with >1.7 million deaths in 218 affected countries. Among these, the United States is the country with the highest number of cases worldwide (16.5 million), followed by India with 9.8 million (updated on December 20, 2020) [6 ].

To contrast the SARS-CoV-2 pandemic, several countries implemented strict preventive measures such as lockdown, store closure, and restrictive international flight travels that appear to have dictated the profile of the SARS-CoV-2 spread on a local scale [7 , 8 , 9 , 10 ]. Moreover, continued and uncontrolled SARS-CoV-2 transmissions worldwide have also created the conditions for significant virus evolution, allowing for the rapid spread and adaptation of new SARS-CoV-2 variants [11 , 12 , 13 , 14 , 15 ]. For this reason, characterization of new variants could lead to a better understanding of the virus transmissibility rate and infection severity and have implications for successful vaccine deployment. In this review, we present a concise characterization of all the lineages and sub-lineages circulating and co-circulating across the world with the aim of determining the magnitude of SARS-CoV-2 threat and better understanding the virus genetic diversity and its dispersion dynamics.

Main Text

As of today, December 20, 2020, 261,487 complete or near-complete genome sequences are publicly available. One of the first available genome was Wuhan-Hu-1 (MN908947.3) sampled on December 26, 2019 in Wuhan, China [3 ], obtained only 6 days after the first SARS-CoV-2 notified case. Since there, open and rapid data sharing through the Global Initiative on Sharing Avian Influenza Data (GISAID) has enabled evolutionary analysis of SARS-CoV-2 on a large scale and in near real time [16 ]. This initiative played an important role in global and European pandemic preparedness and increased our understanding on how fast the virus was spreading and evolving across the world [16 ].

In July 2020, Rambaut et al. [17 ] designed a dynamic nomenclature for SARS-CoV-2 lineage assignment in order to facilitate the real-time genomic epidemiology. By providing commonly agreed labels to refer to viruses circulating in different parts of the world, it was then possible to outline the links between outbreaks that share similar viral genomes. For this purpose, an algorithm named Phylogenetic Assignment of Named Global Outbreak LINeages (pangolin) [17 , 18 ], available at https://github.com/hCoV-2019/pangolin, was implemented.

According to this classification, 2 major lineages at the root of the phylogeny of the SARS-CoV-2 can be distinguished worldwide, namely, lineages A and B [17 ]. Lineage A can be defined by the Wuhan/WH04/2020 sequence and appear to share 2 nucleotides (positions 8,782 in ORF1ab and 28,144 in ORF8) with the closest known bat viruses (RaTG13 and RmYN02). While different nucleotides are present at those sites in viruses assigned to lineage B, which is represented by the Wuhan-Hu-1 strain [17 ].

Most likely, the most recent common ancestor (MRCA) of the SARS-CoV-2 phylogeny shares the same genome sequence as the early lineage A sequences (e.g., Wuhan/WH04/2020) [17 ] even if lineage B was first detected. After the worldwide spread, lineages A and B were further divided into sub-lineages, and other 2 main lineages were detected, namely, lineages C and D that have been recently reassigned as alias of lineage B [12 ]. Furthermore, about 266 lineages/sub-lineages were identified worldwide (see online suppl. Fig. 1; for all online suppl. material, see www.karger.com/doi/10.1159/000515340) (updated up to December 20, 2020).

Currently, the lineage B and sub-lineage B.1 appear to be the most prevalent worldwide, while in Oceania, the most prevalent lineage appears to be D.2 (Fig. 1 ; online suppl. Fig. 1). Additionally, lineage B is the most prevalent in African countries (26.7%), B.1.1 in Asia (13.8%), B.1.177 in Europe (27.7%), B.1 in North America (37.8%), and B.1.1.3 in South America (21.6%). Lineages C and D appear to be likely distributed in a local scale. C.1 and C.2 are mainly found in South Africa (99 and 92%, respectively), whereas C.3 and D1 are mainly found in the UK.

Fig. 1.

Fig. 1

Worldwide lineage distribution. Lineage with a prevalence percentage <2% were grouped as “other.” (For details of the grouped lineages, see online suppl. Table 1.) SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

The ongoing uncontrolled spreading of the SARS-CoV-2 worldwide creates the ideal condition for virus evolution. On this respect, a new SARS-CoV-2 variant (B.1.1.7) has been recently mainly identified in the UK, and from its occurrence, it is spreading rapidly also in other countries [15 ]. This lineage shows an unusually large number of genetic changes, particularly in the S protein (Fig. 2 ). It seems that this variant acquired 17 mutations all at once (14 mutations and 3 deletions), and it has been hypothesized to have an increased likelihood to infect more rapidly and easily human subjects [15 ], but more data are needed to support this hypothesis. A potentially very important mutation, N501Y, detected in the S protein, seems to increase its affinity to the hACE2 receptor, and it has been already identified in over 2,057 individuals in the UK [15 , 19 ]. Thus, it is crucial to constantly monitor all circulating forms in near real time for tracing SARS-CoV-2 epidemic and to promptly implement the proper strategies for disease containment.

Fig. 2.

Fig. 2

Proportion of the new B.1.17 SARS-CoV-2 variants among time. SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

This global effort was also joined by Nextstrain [20 ], an open-source project started in 2018 which integrates the SARS-CoV-2 genomic data updated daily (https://github.com/nextstrain/ncov) to interactively visualize the phylogeny of this emerging viral pathogen to better understand its dispersion dynamic and improve outbreak response [21 , 22 , 23 ]. Thanks to the genomic epidemiology and surveillance, it has been possible to trace the SARS-CoV-2 evolution worldwide. Genetic analyses and surveillance allow for the characterization of circulating viral lineages, the inference of introduction events, and the reconstruction of transmission patterns. Together with epidemiological data, they constitute powerful tools to assist public health initiatives and preparedness.

Conclusion

The active monitoring of all the SARS-CoV-2 variants and/or lineages that are currently circulating and co-circulating around the world highlights the need for enhanced genomic and epidemiological surveillance worldwide in order to rapidly determine the ongoing virus evolution.

Conflict of Interest Statement

The authors have no conflicts of interest to declare.

Funding Sources

This work was supported by CNPq (452537/2019-3). M.G. is supported by Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ).

Author Contributions

Conception and design: E.C., M.G., and M.C. Data curation: E.C. and M.G. Writing − original: E.C. and M.G. Draft preparation: E.C. and M.G. Revision: E.C., M.G., S.F., F.B., A.B., A.P., D.Z., M.C., S.P., G.C., and M.C.

Acknowledgements

We thank all the authors and originating and submitting laboratories that have kindly deposited and shared genome data on GISAID EpiCoV database, on which this research is based.

References


Articles from Chemotherapy are provided here courtesy of Karger Publishers

RESOURCES